Progress, challenges, and opportunities in Francisella vaccine development

References

• Mccoy G, Chapin CV. Bacterium tularense - the cause of a plague-like disease of rodents. Public Health Bulletin. 1912;53:17–23.
   Google Scholar
• Francis E. Tularemia. J Am Med Assoc. 1925;84:1243–1250.
   Google Scholar
• Keim P, Johansson A, Wagner DM. Molecular epidemiology, evolution, and ecology of Francisella. Ann N Y Acad Sci. 2007;1105:30–66.
   PubMed Web of Science ®Google Scholar
• Lyons CR, Wu TH. Animal models of Francisella tularensis infection. Ann N Y Acad Sci. 2007;1105:238–265.
   PubMed Web of Science ®Google Scholar
• Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763–2773.
   PubMed Web of Science ®Google Scholar
• Pavlov VM, Kozlova II, Mokrievich AN, et al. Analysis of Francisella tularensis strains isolated from humans and small rodents during year 2013 tularemia outbreak in Khanty-mansiysk, West Siberia. Presented at: 8th International Conference on Tularemia; 2015 Sep; Opatija, Croatia.
   Google Scholar
• Akalin H, Helvaci S, Gedikoglu S. Re-emergence of tularemia in Turkey. Int J Infect Dis. 2009;13(5):547–551.
   PubMed Web of Science ®Google Scholar
• Cowley SC, Elkins KL. Immunity to Francisella. Front Microbiol. 2011;2:26.
   PubMed Web of Science ®Google Scholar
• Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci. 2007;1105:284–324.
   PubMed Web of Science ®Google Scholar
• Elkins KL, Cowley SC, Bosio CM. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis Live Vaccine Strain. Microbes Infect. 2003;5:135–142.
   PubMed Web of Science ®Google Scholar
• Tärnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis. 1989;11:440–451.
   PubMedGoogle Scholar
• Conlan JW, Oyston PCF. Vaccines against Francisella tularensis. Ann N Y Acad Sci. 2007;1105:325–350.
   PubMed Web of Science ®Google Scholar
• Sandström G, Sjöstedt A, Forsman M, et al. Characterization and classification of strains of Francisella tularensis isolated in the central asian focus of the Soviet Union and in Japan. J Clin Microbiol. 1992;30:172–175.
   PubMed Web of Science ®Google Scholar
• Ellis J, Oyston PCF, Green M, et al. Tularemia. Clin Microbiol Rev. 2002;15(4):631–646.
   PubMed Web of Science ®Google Scholar
• Staples JE, Kubota KA, Chalcraft LG, et al. Epidemiologic and molecular analysis of human tularemia, United States, 1964–2004. Emerg Infect Dis. 2006;12(7):1113–1118.
   PubMed Web of Science ®Google Scholar
• Petersen JM, Molins CR. Subpopulations of Francisella tularensis ssp. tularensis and holarctica: identification and associated epidemiology. Future Microbiol. 2010;5(4):649–661.
   PubMed Web of Science ®Google Scholar
• Kugeler KJ, Mead PS, Janusz AM, et al. Molecular epidemiology of Francisella tularensis in the United States. Clin Infect Dis. 2009;48(7):863–870.
   PubMed Web of Science ®Google Scholar
• Bröms JE, Sjöstedt A, Lavander M. The role of the Francisella tularensis pathogenicity island in Type VI secretion, intracellular survival, and modulation of host cell signaling. Front Microbiol. 2010;1:136.
   PubMed Web of Science ®Google Scholar
• Jones BD, Faron M, Rasmussen JA, et al. Uncovering the components of the Francisella tularensis virulence stealth strategy. Front Cell Infect Microbiol. 2014;4:32.
   PubMed Web of Science ®Google Scholar
• Celli J, Zahrt TC. Mechanisms of Francisella tularensis intracellular pathogenesis. Cold Spring Harb Perspect Med. 2013;3(4):a010314.
   PubMed Web of Science ®Google Scholar
• Gunn JS, Ernst RK. The structure and function of Francisella lipopolysaccharide. Ann N Y Acad Sci. 2007;1105:202–218.
   PubMed Web of Science ®Google Scholar
• Nano FE, Schmerk C. The Francisella pathogenicity island. Ann N Y Acad Sci. 2007;1105:122–137.
   PubMed Web of Science ®Google Scholar
• Nano FE, Zhang N, Cowley SC, et al. A Francisella tularensis pathogenicity island required for intramacrophage growth. J Bacteriol. 2004;186(19):6430–6436.
   PubMed Web of Science ®Google Scholar
• Bosio CM, Bielefeldt-Ohmann H, Belisle JT. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol. 2007;178(7):4538–4547.
   PubMed Web of Science ®Google Scholar
• Gillette DD, Curry HM, Cremer T, et al. Virulent Type A Francisella tularensis actively suppresses cytokine responses in human monocytes. Front Cell Infect Microbiol. 2014;4:45.
   PubMed Web of Science ®Google Scholar
• Cowley SC, Myltseva SV, Nano FE. Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity, and nitric oxide production. Mol Microbiol. 1996;20:867–874.
   PubMed Web of Science ®Google Scholar
• Eigelsbach HT, Downs CM. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol. 1961;87:415–425.
   PubMed Web of Science ®Google Scholar
• Waag DM, Galloway A, Sändstrom G, et al. Cell-mediated and humoral immune responses induced by scarification vaccination of human volunteers with a new lot of the Live Vaccine Strain of Francisella tularensis. J Clin Microbiol. 1992;30(9):2256–2264.
   PubMed Web of Science ®Google Scholar
• Conlan JW. Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol. 2011;6:391–405.
   PubMed Web of Science ®Google Scholar
• Tigertt WD. Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev. 1962;26:354–373.
   PubMedGoogle Scholar
• Feodorova VA, Sayapina LV, Corbel MJ, et al. Russian vaccines against especially dangerous bacterial pathogens. Emerg Microbes Infect. 2014;3(12):e86.
   PubMed Web of Science ®Google Scholar
• Sändstrom G. The tularemia vaccine. J Chem Tech Biotechnol. 1994;59:315–320.
   PubMed Web of Science ®Google Scholar
• Eigelsbach HT, Hornick RB, Tulis JJ. Recent studies on live tularemia vaccine. Med Ann Dist Columbia. 1967;36(5):282–286.
   PubMedGoogle Scholar
• Eigelsbach HT, Tulis JJ, Mcgavran MH, et al. Live tularemia vaccine. I. Host-parasite relationship in monkeys vaccinated intracutaneously or aerogenically. J Bacteriol. 1962;84:1020–1027.
   PubMed Web of Science ®Google Scholar
• National Research Council. Protecting the frontline in biodefense research: the special immunizations program. Washington (DC): The National Academies Press; 2011.
   Google Scholar
• Pasetti MF, Cuberos L, Horn TL, et al. An improved Francisella tularensis Live Vaccine Strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine. 2008;26(14):1773–1785.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Atmar RL, Patel SM, et al. Safety, reactogenicity and immunogenicity of Francisella tularensis Live Vaccine Strain in humans. Vaccine. 2009;27(36):4905–4911.
   PubMed Web of Science ®Google Scholar
• Hornick RB, Eigelsbach HT. Aerogenic immunization of man with live tularemia vaccine. Bacteriol Rev. 1966;30(3):532–538.
   PubMedGoogle Scholar
• Saslaw S, Eigelsbach HT, Prior JA, et al. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961;107:134–146.
   Google Scholar
• Mccrumb FR. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev. 1961;25:262–267.
   PubMedGoogle Scholar
• Petrosino JF, Xiang Q, Karpathy SE, et al. Chromosome rearrangement and diversification of Francisella tularensis revealed by the type B (OSU18) genome sequence. J Bacteriol. 2006;188(19):6977–6985.
   PubMed Web of Science ®Google Scholar
• Rohmer L, Fong C, Abmayr S, et al. Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strains. Genome Biol. 2007;8(6):R102.
   PubMed Web of Science ®Google Scholar
• Salomonsson E, Kuoppa K, Forslund A-L, et al. Reintroduction of two deleted virulence loci restores full virulence to the Live Vaccine Strain of Francisella tularensis. Infect Immun. 2009;77(8):3424–3431.
   PubMed Web of Science ®Google Scholar
• Marohn ME, Barry EM. Live attenuated tularemia vaccines: recent developments and future goals. Vaccine. 2013;31(35):3485–3491.
   PubMed Web of Science ®Google Scholar
• Burke DS. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis. 1977;135:55–60.
   PubMed Web of Science ®Google Scholar
• Rusnak JM, Kortepeter MG, Hawley RJ, et al. Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecur Bioterror. 2004;2(4):281–293.
   PubMedGoogle Scholar
• Fulton KM, Zhao X, Petit MD, et al. Immunoproteomic analysis of the human antibody response to natural tularemia infection with Type A or Type B strains or LVS vaccination. Int J Med Microbiol. 2011;301(7):591–601.
   PubMed Web of Science ®Google Scholar
• Chu P, Cunningham AL, Yu J-J, et al. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. PLoS Pathog. 2014;10(10):e1004439.
   PubMed Web of Science ®Google Scholar
• Saslaw S, Eigelsbach HT, Wilson HE, et al. Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med. 1961;107:121–133.
   PubMedGoogle Scholar
• Ericsson M, Sandström G, Sjöstedt A, et al. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J Infect Dis. 1994;170:110–114.
   PubMed Web of Science ®Google Scholar
• Eneslätt K, Rietz C, Rydén P, et al. Persistence of cell-mediated immunity three decades after vaccination with the Live Vaccine Strain of Francisella tularensis. Eur J Immunol. 2011;41(4):974–980.
   PubMed Web of Science ®Google Scholar
• Gries DM, Fairchok MP. Typhoidal tularemia in a human immunodeficiency virus-infected adolescent. Pediatr Infect Dis J. 1996;15(9):838–840.
   PubMed Web of Science ®Google Scholar
• Karttunen R, Surcel HM, Andersson G, et al. Francisella tularensis-induced in vitro gamma interferon, tumor necrosis factor alpha, and interleukin 2 responses appear within 2 weeks of tularemia vaccination in human beings. J Clin Microbiol. 1991;29(4):753–756.
   PubMed Web of Science ®Google Scholar
• Eneslätt K, Normark M, Björk R, et al. Signatures of T cells as correlates of immunity to Francisella tularensis. PLoS One. 2012;7(3):e32367.
   PubMed Web of Science ®Google Scholar
• Reed DS, Smith LP, Cole KS, et al. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun. 2014;82(5):2098–2105.
   PubMed Web of Science ®Google Scholar
• Eigelsbach HT, Tulis JJ, Overholt EL, et al. Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proc Soc Exp Biol Med. 1961;108:732–734.
   PubMed Web of Science ®Google Scholar
• Tulis JJ, Eigelsbach HT, Kerpsack RW. Host-parasite relationship in monkeys administered live tularemia vaccine. Am J Pathol. 1970;58(2):329–336.
   PubMed Web of Science ®Google Scholar
• Mcgavran MH, White JD, Eigelsbach HT, et al. Morphologic and immunohistochemical studies of the pathogenesis of infection and antibody formation subsequent to vaccination of Macaca irus with an attenuated strain of Pasteurella tularensis: I. Intracutaneous vaccination. Am J Pathol. 1962;41(3):259–271.
   PubMed Web of Science ®Google Scholar
• White JD, Mcgavran MH, Prickett PA, et al. Morphologic and immunohistochemical studies of the pathogenesis of infection and antibody formation subsequent to vaccination of Macaca irus with an attenuated strain of Pasteurella tularensis: II. Aerogenic vaccination. Am J Pathol. 1962;41(4):405–413.
   PubMed Web of Science ®Google Scholar
• Day WC, Berendt RF. Experimental tularemia in Macaca mulatta: relationship of aerosol particle size to the infectivity of airborne Pasteurella tularensis. Infect Immun. 1972;5(1):77–82.
   PubMed Web of Science ®Google Scholar
• Eigelsbach HT, Saslaw S, Tulis JJ, et al. Tularemia: the monkey as a model for man. San Antonio (TX): Southwestern Foundation for Research and Education; 1968.
   Google Scholar
• Nelson M, Lever MS, Dean RE, et al. Characterization of lethal inhalational infection with Francisella tularensis in the common marmoset (Callithrix jacchus). J Med Microbiol. 2010;59(Pt 9):1107–1113.
   PubMed Web of Science ®Google Scholar
• Nelson M, Lever MS, Savage VL, et al. Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus). Int J Exp Pathol. 2009;90(2):109–118.
   PubMed Web of Science ®Google Scholar
• Glynn AR, Alves DA, Frick O, et al. Comparison of experimental respiratory tularemia in three nonhuman primate species. Comp Immunol Microbiol Infect Dis. 2015;39:13–24.
   PubMed Web of Science ®Google Scholar
• Tulis JJ, Eigelsbach HT, Hornick RB. Oral vaccination against tularemia in the monkeys. Proc Soc Exp Biol Med. 1969;132(3):893–897.
   PubMed Web of Science ®Google Scholar
• Ray HJ, Chu P, Wu TH, et al. The Fischer 344 rat reflects human susceptibility to Francisella pulmonary challenge and provides a new platform for virulence and protection studies. PLoS One. 2010;5(4):e9952.
   PubMed Web of Science ®Google Scholar
• Wu TH, Zsemlye JL, Statom GL, et al. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine. 2009;27(34):4684–4693.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Dang KM, Yu J-J, et al. Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB:: fljB. Vaccine. 2014;32(40):5234–5240.
   PubMed Web of Science ®Google Scholar
• Mara-Koosham G, Hutt JA, Lyons CR, et al. Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect Immun. 2011;79(4):1770–1778.
   PubMed Web of Science ®Google Scholar
• Conlan JW, Chen W, Bosio CM, et al. Infection of mice with Francisella as an immunological model. Curr Protoc Immunol. 2011;93:19.14.11–19.14.16.
   Google Scholar
• Chen W, Shen H, Webb A, et al. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine. 2003;21(25–26):3690–3700.
   PubMed Web of Science ®Google Scholar
• Cole LE, Yang Y, Elkins KL, et al. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A. 2009;106(11):4343–4348.
   PubMed Web of Science ®Google Scholar
• Twine SM, Petit MD, Shen H, et al. Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines. Biochem Biophys Res Commun. 2006;346(3):999–1008.
   PubMed Web of Science ®Google Scholar
• Lavine CL, Clinton SR, Angelova-Fischer I, et al. Immunization with heat-killed Francisella tularensis LVS elicits protective antibody-mediated immunity. Eur J Immunol. 2007;37(11):3007–3020.
   PubMed Web of Science ®Google Scholar
• De Pascalis R, Mittereder L, Chou AY, et al. Francisella tularensis vaccines elicit concurrent protective T- and B-cell immune responses in BALB/cByJ mice. PLoS One. 2015;10(5):e0126570.
   Web of Science ®Google Scholar
• Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis Live Vaccine Strain. Infect Immun. 1999;67:6002–6007.
   PubMed Web of Science ®Google Scholar
• Conlan JW, Sjöstedt A, North RJ. CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun. 1994;62:5603–5607.
   PubMed Web of Science ®Google Scholar
• Griffin AJ, Crane DD, Wehrly TD, et al. Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells. Clin Vaccine Immunol. 2015;22(1):119–128.
   PubMed Web of Science ®Google Scholar
• Cowley SC, Elkins KL. Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp Med. 2003;198(3):379–389.
   PubMed Web of Science ®Google Scholar
• Cowley SC, Hamilton E, Frelinger JA, et al. CD4−CD8− T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med. 2005;202(2):309–319.
   PubMed Web of Science ®Google Scholar
• Cowley SC, Meierovics AI, Frelinger JA, et al. Lung CD4−CD8− double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis Live Vaccine Strain. J Immunol. 2010;184(10):5791–5801.
   PubMed Web of Science ®Google Scholar
• Meierovics A, Yankelevich W-JC, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl Acad Sci U S A. 2013;110(33):E3119–E3128.
   PubMed Web of Science ®Google Scholar
• Elkins KL, Cowley SC, Conlan JW. Measurement of macrophage-mediated killing of intracellular bacteria, including Francisella and Mycobacteria. Curr Protoc Immunol. 2011;93:14.25.11–14.25.13.
   Google Scholar
• De Pascalis R, Chou AY, Bosio CM, et al. Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathog. 2012;8(1):e1002494.
   PubMed Web of Science ®Google Scholar
• De Pascalis R, Chou AY, Ryden P, et al. Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS). MBio. 2014;5(2):e00936-13.
   PubMed Web of Science ®Google Scholar
• Yee D, Rhinehart-Jones TR, Elkins KL. Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol. 1996;157:5042–5048.
   PubMed Web of Science ®Google Scholar
• Poquet Y, Kroca M, Halary F, et al. Expansion of Vgamma9 Vdelta2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect Immun. 1998;66(5):2107–2114.
   PubMed Web of Science ®Google Scholar
• Kurtz SL, Foreman O, Bosio CM, et al. Interleukin-6 is essential for primary resistance to Francisella tularensis Live Vaccine Strain infection. Infect Immun. 2013;81(2):585–597.
   PubMed Web of Science ®Google Scholar
• Melillo AA, Foreman O, Elkins KL. IL-12Rβ2 is critical for survival of primary Francisella tularensis LVS infection. J Leukoc Biol. 2013;93(5):657–667.
   PubMed Web of Science ®Google Scholar
• Melillo AA, Foreman O, Bosio CM, et al. T-bet regulates immunity to Francisella tularensis Live Vaccine Strain infection, particularly in lungs. Infect Immun. 2014;82(4):1477–1490.
   PubMed Web of Science ®Google Scholar
• Snoy PJ. Establishing efficacy of human products using animals: the US Food and Drug Administration’s “animal rule”. Vet Pathol. 2010;47(5):774–778.
   PubMed Web of Science ®Google Scholar
• Ryden P, Twine S, Shen H, et al. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria. Mol Immunol. 2013;54(1):58–67.
   PubMed Web of Science ®Google Scholar
• Twine S, Shen H, Harris G, et al. BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Vaccine. 2012;30(24):3634–3645.
   PubMed Web of Science ®Google Scholar
• Shen H, Harris G, Chen W, et al. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One. 2010;5(10):e13349.
   PubMed Web of Science ®Google Scholar
• De Pascalis R, Mittereder L, Kennett NJ, et al. Activities of murine peripheral blood lymphocytes provide immune correlates that predict Francisella tularensis vaccine efficacy. Infect Immun. 2016;84:1054–1061.
   PubMed Web of Science ®Google Scholar
• Waag DM, Sändstrom G, England MJ, et al. Immunogenicity of a new lot of Francisella tularensis live vaccine strain in human volunteers. FEMS Immunol Med Microbiol. 1996;13(3):205–209.
   PubMedGoogle Scholar
• Waag DM, Mckee KT Jr, Sandstrom G, et al. Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin Diagn Lab Immunol. 1995;2(2):143–148.
   PubMedGoogle Scholar
• Paranavitana C, Pittman PR, Velauthapillai M, et al. Transcriptional profiling of Francisella tularensis infected peripheral blood mononuclear cells: a predictive tool for tularemia. FEMS Immunol Med Microbiol. 2008;54(1):92–103.
   PubMedGoogle Scholar
• Paranavitana C, Zelazowska E, Dasilva L, et al. Th17 cytokines in recall responses against Francisella tularensis in humans. J Interferon Cytokine Res. 2010;30(7):471–476.
   PubMed Web of Science ®Google Scholar
• Bosio CM, Elkins KL. Susceptibility to secondary Francisella tularensis Live Vaccine Strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity. Infect Immun. 2001;69:194–203.
   PubMed Web of Science ®Google Scholar
• Elkins KL, Cooper A, Colombini SM, et al. In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of Interleukin-12 (IL-12) but not on IL-12 p70. Infect Immun. 2002;70:1936–1948.
   PubMed Web of Science ®Google Scholar
• Sandström G, Löfgren S, Tärnvik A. A capsule-deficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing by serum but diminished sensitivity to killing by polymorphonuclear leukocytes. Infect Immun. 1988;56:1194–1202.
   PubMed Web of Science ®Google Scholar
• Kurtz SL, Elkins KL. Correlates of vaccine-induced protection against Mycobacterium tuberculosis revealed in comparative analyses of lymphocyte populations. Clin Vaccine Immunol. 2015;22:1096–1108.
   PubMed Web of Science ®Google Scholar
• Elkins KL, Colombini SM, Meierovics AI, et al. Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma. Microbes Infect. 2010;12(1):28–36.
   PubMed Web of Science ®Google Scholar
• Hewetson JF, Little SF, Ivins BE, et al. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine. 2008;26(33):4262–4266.
   PubMed Web of Science ®Google Scholar
• Fay MP, Follmann DA, Lynn F, et al. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med. 2012;4(151):151ra126.
   PubMed Web of Science ®Google Scholar
• Chen L, Schiffer JM, Dalton S, et al. Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques. Clin Vaccine Immunol. 2014;21(11):1512–1520.
   PubMed Web of Science ®Google Scholar
• Williamson ED, Oyston PC. Protecting against plague: towards a next-generation vaccine. Clin Exp Immunol. 2013;172(1):1–8.
   PubMed Web of Science ®Google Scholar
• Silva EB, Goodyear A, Sutherland MD, et al. Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine. Infect Immun. 2013;81(12):4626–4634.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Worku S, Kampmann B, et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis. 2002;186(10):1448–1457.
   PubMed Web of Science ®Google Scholar
• Ohtake S, Martin RA, Saxena A, et al. Formulation and stabilization of Francisella tularensis Live Vaccine Strain. J Pharm Sci. 2011;100(8):3076–3087.
   PubMed Web of Science ®Google Scholar